Monoclonal antibodies currently in Phase II and III trials for multiple myeloma

Expert Opin Biol Ther. 2014 Aug;14(8):1127-44. doi: 10.1517/14712598.2014.908848. Epub 2014 Apr 21.


Introduction: Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed. mAbs are a new promising anticancer treatment option.

Areas covered: This review will focus on mAbs that are currently under evaluation in Phase II and III clinical trials, as single agent and in combination with established treatment options.

Expert opinion: mAbs are a new strategy against MM, and they have demonstrated encouraging results in preclinical models. mAbs have a relatively benign side-effect profile and work synergistically with traditional chemotherapies and with immunomodulatory drugs and proteasome inhibitors.

Keywords: antibodies; monoclonal; multiple myeloma.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Cells / immunology
  • Bone Marrow Cells / pathology
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Lenalidomide
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / pathology
  • Pyrazines / administration & dosage
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Tumor Microenvironment / immunology


  • Antibodies, Monoclonal
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Lenalidomide